ViRexx Medical Corp.
TSX : VIR
AMEX : REX

ViRexx Medical Corp.

May 19, 2006 17:42 ET

ViRexx to Present at SMi Third Biannual Vaccines Conference

EDMONTON, ALBERTA--(CCNMatthews - May 19, 2006) - ViRexx Medical Corp. (TSX:VIR) (AMEX:REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced that Dr. Rajan George, Vice President Research, is scheduled to present at the upcoming SMi 3rd Biannual Conference, Vaccines - From Bench to Bedside. Dr. George's presentation titled "Chimigen Vaccine Platform: A Novel, Versatile and Adaptable Platform for Vaccine Development" is scheduled for Monday, May 22, 2006 at 2:20 p.m. local time. The SMi conference is held in Central London, UK from May 22 - 23, 2006.

Dr. George will also participate in a panel discussion focused on government and industry perspectives in vaccine development in response to bioterrorism.

The SMi conference will feature international case studies and perspectives from leaders in the vaccine field, and will address key issues such as vaccine development, clinical trials, and delivery systems. Other topics include public health preparedness, new technologies and legislative compliance.

About the Chimigen™ Technology

ViRexx's Chimigen™ Vaccine platform is a technology that incorporates functional elements of an antigen and a murine monoclonal antibody through recombinant technology. These new classes of vaccines are designed to elicit both a humoral (antibody) and cellular immune responses against the target antigen. ViRexx has received authorization from Health Canada to undertake a Phase I clinical trial for its lead Chimigen™ Vaccine candidate, HepaVaxx B Vaccine, a potential treatment for chronic carriers of hepatitis B virus.

About ViRexx Medical Corp.

ViRexx is an Edmonton, Alberta based biotechnology company focused on the development of novel therapeutic products for the treatment of certain cancers and specified chronic viral infections. ViRexx's most advanced programs include drug candidates for the treatment of ovarian cancer, chronic hepatitis B and C and solid tumors.

ViRexx's lead product candidate, OvaRex® MAb, a therapy for the treatment of late-stage ovarian cancer, is currently the subject of two Phase III clinical trials being funded by ViRexx's licensing partner Unither Pharmaceuticals, Inc., a subsidiary of United Therapeutics Corporation. For additional information about ViRexx, please see www.virexx.com.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of the Company with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

Contact Information

  • ViRexx Medical Corp.
    Marc Canton
    President & Chief Operating Officer
    (780) 433-4411
    (780) 436-0068 (FAX)
    Email: mcanton@virexx.com
    or
    Fyre Marketing
    Chris Marcus
    Investor Relations
    (512) 542-9916